Publication: Sequential <sup>18</sup>F-fluorodeoxyglucose positron emission tomography (<sup>18</sup>F-FDG PET) scan findings in patients with extrapulmonary tuberculosis during the course of treatment—a prospective observational study
Issued Date
2020-01-01
Resource Type
ISSN
16197089
16197070
16197070
Other identifier(s)
2-s2.0-85085875596
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
European Journal of Nuclear Medicine and Molecular Imaging. (2020)
Suggested Citation
Jamshed Bomanji, Rajnish Sharma, Bhagwant R. Mittal, Sanjay Gambhir, Ahmad Qureshy, Shamim M.F. Begum, Diana Paez, Mike Sathekge, Mariza Vorster, Dragana Sobic Saranovic, Pawana Pusuwan, Vera Mann, Sobhan Vinjamuri, Alimuddin Zumla, Thomas N.B. Pascual Sequential <sup>18</sup>F-fluorodeoxyglucose positron emission tomography (<sup>18</sup>F-FDG PET) scan findings in patients with extrapulmonary tuberculosis during the course of treatment—a prospective observational study. European Journal of Nuclear Medicine and Molecular Imaging. (2020). doi:10.1007/s00259-020-04888-7 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/58339
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Sequential <sup>18</sup>F-fluorodeoxyglucose positron emission tomography (<sup>18</sup>F-FDG PET) scan findings in patients with extrapulmonary tuberculosis during the course of treatment—a prospective observational study
Other Contributor(s)
Klinicki Centar Srbije
Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow
University College London Hospitals NHS Foundation Trust
Royal Liverpool University Hospital
Osterreichische Institut fur Internationale Politik
Universiteit van Pretoria
International Atomic Energy Agency, Vienna
Faculty of Medicine, Siriraj Hospital, Mahidol University
Bangabandhu Sheikh Mujib Medical University
Institute of Nuclear Medicine and Allied Sciences India
Postgraduate Institute of Medical Education & Research, Chandigarh
Institute of Nuclear Medicine and Oncology (INMOL)
Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow
University College London Hospitals NHS Foundation Trust
Royal Liverpool University Hospital
Osterreichische Institut fur Internationale Politik
Universiteit van Pretoria
International Atomic Energy Agency, Vienna
Faculty of Medicine, Siriraj Hospital, Mahidol University
Bangabandhu Sheikh Mujib Medical University
Institute of Nuclear Medicine and Allied Sciences India
Postgraduate Institute of Medical Education & Research, Chandigarh
Institute of Nuclear Medicine and Oncology (INMOL)
Abstract
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature. Background: Initial studies of tuberculosis (TB) in macaques and humans using 18F-FDG positron emission tomography (PET) imaging as a research tool suggest its usefulness in localising disease sites and as a clinical biomarker. Sequential serial scans in patients with extrapulmonary TB (EPTB) could inform on the value of PET-CT for monitoring response to treatment and defining cure. Patients and methods: HIV-negative adults with EPTB from eight sites across six countries had three 18F-FDG PET/CT scans: (i) within 2 weeks of enrolment, (ii) at 2 months into TB treatment and (iii) at end of ATT treatment. Scanning was performed according to the EANM guidelines. 18F-FDG PET/CT scans were performed 60 ± 10 min after intravenous injection of 2.5–5.0 MBq/kg of 18F-FDG. Findings: One hundred and forty-seven patients with EPTB underwent 3 sequential scans. A progressive reduction over time of both the number of active sites and the uptake level (SUVmax) at these sites was seen. At the end of WHO recommended treatment, 53/147 (36.0%) patients had negative PET/CT scans, and 94/147 (63.9%) patients remained PET/CT positive, of which 12 patients had developed MDR TB. One died of brain tuberculoma. Interpretation: Current 18F-FDG PET/CT imaging technology cannot be used clinically as a biomarker of treatment response, cure or for decision-making on when to stop EPTB treatment. PET/CT remains a research tool for TB and further development of PET/CT is required using new Mycobacterium tuberculosis-specific radiopharmaceuticals targeting high-density surface epitopes, gene targets or metabolic pathways.